These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25586981)

  • 41. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
    Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
    Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
    Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
    Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Detection of minimal residual disease in childhood B-ALL by flow cytometry].
    Xu C; Zhao HJ; Wu ZH; Xue HL; Tang JY; Chen J; Pan C; Chen J; Li L; Gu LJ; Shen LS
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jun; 24(6):295-9. PubMed ID: 12859864
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of CD11c expression in the diagnosis of mantle cell lymphoma.
    Kraus TS; Sillings CN; Saxe DF; Li S; Jaye DL
    Am J Clin Pathol; 2010 Aug; 134(2):271-7. PubMed ID: 20660331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.
    Böttcher S; Stilgenbauer S; Busch R; Brüggemann M; Raff T; Pott C; Fischer K; Fingerle-Rowson G; Döhner H; Hallek M; Kneba M; Ritgen M
    Leukemia; 2009 Nov; 23(11):2007-17. PubMed ID: 19641522
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia.
    van Stijn A; Kok A; van der Pol MA; Feller N; Roemen GM; Westra AH; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2003 Apr; 17(4):780-6. PubMed ID: 12682637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
    Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
    Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance.
    Ladetto M; Tavarozzi R; Pott C
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):887-901. PubMed ID: 32861285
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Flow cytometric monitoring of minimal residual diseases in patients with acute leukemia after allogeneic hemapoietic stem cell transplantation].
    Gao YQ; Wu T; Wang H; Tong CR; Zhang WJ; Wang JB; Lu Y; Zhao YL; Zhou JR; Sun Y; Zhang YC; Ji SQ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):84-7. PubMed ID: 22730653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.
    Solly F; Angelot F; Garand R; Ferrand C; Seillès E; Schillinger F; Decobecq A; Billot M; Larosa F; Plouvier E; Deconinck E; Legrand F; Saas P; Rohrlich PS; Garnache-Ottou F
    Cytometry A; 2012 Jan; 81(1):17-24. PubMed ID: 22052678
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
    Al-Mawali A; Gillis D; Hissaria P; Lewis I
    Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients.
    Morice WG; Kurtin PJ; Hodnefield JM; Shanafelt TD; Hoyer JD; Remstein ED; Hanson CA
    Mayo Clin Proc; 2008 Jul; 83(7):776-85. PubMed ID: 18613994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of SOX11 immunostaining in confirming the diagnosis of mantle cell lymphoma on fine-needle aspiration samples.
    Zhang YH; Liu J; Dawlett M; Guo M; Sun X; Gong Y
    Cancer Cytopathol; 2014 Dec; 122(12):892-7. PubMed ID: 25056830
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.
    Borowitz MJ; Pullen DJ; Shuster JJ; Viswanatha D; Montgomery K; Willman CL; Camitta B;
    Leukemia; 2003 Aug; 17(8):1566-72. PubMed ID: 12886244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
    Wu S; Blombery P; Westerman D; Tam CS
    Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical value of minimal residual disease detection by flow cytometry in childhood B-cell acute lymphoblastic leukemia].
    Chang L; Zhang G; Shi H; Ye L; Jiang YM
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Dec; 16(12):1245-9. PubMed ID: 25523574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
    Ruiz-Argüelles GJ; Fernández-Lara D; Estrada-Gómez R; Manzano C; Ruiz-Delgado GJ; Pérez-Romano B; Ruiz-Argüelles A
    Lab Hematol; 2007; 13(1):22-6. PubMed ID: 17353179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.